28328-61-2

Upstream product

• 22892-95-1 4-chloro-5-chlorosulphonyl-3-nitro-benzoic acid 
• 124-40-3 dimethyl amine 
• 2494-79-3 4-chloro-3-(chlorosulfonyl)benzoic acid 

Downstream Products

• 1357465-18-9 4-chloro-3-dimethylsulfamoyl-5-nitro-benzoic acid methyl ester 
• 1357465-22-5 3-butyrylamino-5-dimethylsulfamoyl-4-phenoxy-benzoic acid methyl ester 
• 1357465-21-4 3-amino-5-dimethylsulfamoyl-4-phenoxy-benzoic acid methyl ester 
• 1357465-19-0 3-dimethylsulfamoyl-5-nitro-4-phenoxy-benzoic acid methyl ester 
• 1357459-65-4 3-dibutylamino-5-dimethylsulfamoyl-4-phenoxy-benzoic acid 
• 100563-16-4 3-(butylamino)-5-(N,N-dimethylsulfamoyl)-4-phenoxybenzoic acid 
• 28468-97-5 ethyl 3-benzylamino-5-dimethylsulphamyl-4-phenoxy-benzoate 
• 28468-98-6 3-benzylamino-5-dimethylsulphamyl-4-phenoxy-benzoic acid 
• 28328-57-6 3-(N,N-dimethylsulfamoyl)-5-nitro-4-phenoxybenzoic acid 

Relevant academic research and scientific papers

ARYLSULFONAMIDE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE

The present invention provides acylsulfonamides including bumetanide derivatives and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these compounds and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na+K+Cl- co-transporter or GABAA receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders (autism), bipolar disorder, cancer, the improvement of cognitive function, cognitive impairment, cognitive dysfunction, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, inflammatory pain, insomnia, ischemia, migraine, migraine with aura, migraine without aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, periodic limb movement disorder (PLMD), personality disorders, postherpetic neuralgia, psychosis, restless legs syndrome (RLS), schizophrenia, seizure disorders, spasticity, tinnitus, and withdrawal syndromes.

3-Amino, 4-thio-substituted, 5-sulphamyl-benzoic acid derivatives

This invention relates to new, therapeutically active compounds of the general formula SPC1 In which A represents one of the groupings EQU1 R2 --O--, R2 --S--, R2 --OS--, and R2 --O2 S--, R1, R2, R3, and R4 each represents hydrogen, an aliphatic radical, a cycloaliphatic radical, or an aromatically, cycloaliphatically, or heterocyclically substituted aliphatic radical, in addition to which R2 and R3 may each represent an aromatic or heterocyclic radical, and when A is EQU2 R1 and R2 may be linked to form a 5- to 8-membered heterocyclic ring system, which may have one or more nitrogen atoms, sulphur atoms, or oxygen atoms in addition to the nitrogen atom linked to R1 and R2 ; R5 is hydrogen or lower alkyl; and R6 is hydrogen or lower alkyl or acyl; to salts, esters, and amides of the said compounds; and to methods for the production of the compounds.